WVE Wave Life Sciences Ltd. Insider Trading

RA Capital Management bought 8,772,496 shares at $6.23 blended average, expanding stake to 26.98M shares (+48.2%), while WVE stock is down -68.9% from 52-week high.

RA Capital Management, a director at Wave Life Sciences, executed 4 separate purchases totaling 8,772,496 shares for $54,624,377.99 between March 26–30, 2026, at a blended average price of $6.23. This represents a material 48.2% increase in the director's holdings from 18.20M to 26.98M shares. The accumulation is notable given WVE's recent performance: the stock currently trades at $6.62, down -68.9% from its 52-week high of $21.31 and down -52.5% over the past 30 days. Underlying fundamentals show deterioration: the company generated $8.7M in quarterly revenue (down -60.6% year-over-year), posted a net loss of $53.9M, and remains unprofitable. The insider's cross-ticker track record shows strong historical buy outcomes (11 prior buys, 100% 90-day win rate, avg 90d return +69.8%), though this signals buying discipline more broadly rather than predictive power specific to WVE, where measurable same-ticker outcomes are absent.

GSK (10% owner) adds 1,470,000 shares of WVE at $19.00; stake rises to 18.25M (+8.8%). Stock now -24.4% from 52-week high, unprofitable company.

GSK plc, a 10% shareholder, purchased 1,470,000 shares at $19.00 on 2025-12-11, increasing its position to 18,245,691 shares from 16,775,691 shares pre-transaction. This represents an additional $27,930,000.00 commitment at a price well above the current $16.11 market level, with the stock trading -24.4% from its 52-week high of $21.31. Notably, Wave Life Sciences remains fundamentally challenged—the company generated only $8.7M in revenue last quarter and posted a net loss of $53.9M, with annual revenue declining 4.4% year-over-year and the company unprofitable over its most recent full fiscal year. GSK's prior two trades at WVE both showed strong 90-day returns (+80.6% and +25.8%), establishing a pattern of well-timed entry points; however, the current purchase at $19.00 sits at a price level above today's market, raising questions about near-term momentum and the timing of this latest accumulation against the company's deteriorating financial trajectory.

Francis Chris sold 441,031 shares (94.6% of holdings) in 9 transactions for $6.4M on 2025-12-08; stock up 187% in 30 days.

Francis Chris executed 9 separate sales totaling 441,031 shares for $6,427,084.96 at a blended average price of $14.57, reducing his holdings from 466,031 shares to 25,000 shares. His prior trades at Wave Life Sciences show a 100% well-timed pattern at the 90-day mark (all 4 prior sales preceded declines), suggesting a track record of selling ahead of downturns at this ticker. However, the current stock price of $20.23 sits +187.0% above the transaction price within just 30 days, contradicting the timing signal from his historical pattern. The company's recent fundamentals reveal net income of $-53,852,000 and negative annual revenue growth of -4.4%, yet the stock has surged dramatically since his sales, indicating either a strong market-driven rally decoupled from fundamentals or a significant market reassessment not yet reflected in the latest reported numbers.

Director HENRY CHRISTIAN O sold 93.4K shares (88.0% of holdings) for $1.4M across 4 transactions on 2025-12-08

HENRY CHRISTIAN O executed 4 separate sales totaling 93,445 shares for $1,369,323.75, reducing his holding from 106.1K to 12.7K shares. The sales occurred at prices ranging from $12.75 to $18.02, with a blended average of $14.65, occurring while the stock currently trades at $20.23 (up 187.0% over 30 days and 182.5% over 90 days). Despite the sharp recent rally, the director liquidated nearly 88% of his position at prices well below the current market. The company reported a net loss of $-53.9M on revenue of $8.7M in the latest quarter and declined 4.4% year-over-year, though it maintains a $3.4B market cap. The director's cross-ticker track record shows 1 prior sell with a 100.00% well-timed rate (measuring 90-day post-sale declines), though this represents limited same-ticker precedent at Wave Life Sciences.

CFO Kyle Moran sold 260,036 shares for $4,103,979.00 at Wave Life Sciences on 2025-12-08/09, reducing holdings by 74.2%

Kyle Moran, CFO of Wave Life Sciences, executed 6 separate sales totaling 260,036 shares for $4,103,979.00 across December 8–9, 2025, at prices ranging from $13.20 to $20.25 and a blended average of $15.78. This sale reduced his holdings from 350,401 shares to 90,365 shares, a -74.2% reduction. The timing coincides with notable stock appreciation: the company has appreciated 187.0% over the prior 30 days and 182.5% over 90 days, from a 52-week low of $5.48 toward a 52-week high of $21.31 (current price $20.23, -5.1% from peak). Against this backdrop, the company remains unprofitable with net income of $-53,852,000.00 on $8,699,000.00 in latest quarterly revenue, and has experienced -4.4% annual revenue decline. The substantial reduction in the CFO's stake during a period of steep price appreciation in an unprofitable business warrants investor attention to the underlying fundamentals and whether the recovery in valuation is sustainable.

Director Tan Aik Na sold 134,218 shares for $1,823,158.50, reducing holdings by 84.1% in 8 separate transactions on 2025-12-08

Director Tan Aik Na executed 8 separate sales on 2025-12-08 totaling 134,218 shares for $1,823,158.50, reducing his holdings from 159,618 shares to 25,400 shares—a reduction of 84.1% of his pre-transaction position. The sales occurred at two distinct price points ($12.75 and $15.00), with a blended average price of $13.58, and follow a period of significant stock appreciation: the stock has risen 187.0% over the prior 30 days and 182.5% over the prior 90 days. The company remains unprofitable with a net income of $-53,852,000.00 against quarterly revenue of $8,699,000.00, and annual revenue is declining at -4.4%. The substantial scale of the liquidation—84.1% of holdings—combined with the dramatic recent price appreciation and the company's ongoing unprofitability, represents material insider activity that warrants investor attention.

RA Capital Management Director buys 1,000 shares of WVE at $6.69; stock down 56.9% from 52-week high amid unprofitable operations.

RA Capital Management, L.P. purchased 1,000 shares at $6.69, a modest transaction representing a 0.0% increase to an already substantial 18.20M share position, in a company trading 56.9% below its 52-week high of $16.44. Wave Life Sciences continues to operate unprofitably with a net loss of $-53.9M against quarterly revenue of $8.7M and annual revenue decline of -4.4%, indicating structural operational challenges. Across all tickers, the insider's historical track record shows 2 prior buys against 18 prior sells, suggesting a predominantly exit-oriented pattern. The combination of a financially distressed issuer, steep recent price declines, and this insider's historical preference for liquidation over accumulation suggests the purchase reflects a relatively small, non-directional position adjustment rather than a material conviction signal.

CEO BOLNO PAUL sold 217.4K shares at $10.10, reducing stake -64.2% to 121.0K shares; prior 4 WVE sales all declined 90-day post-sale.

BOLNO PAUL executed a substantial divestiture, selling 217,351 shares for $2,194,810.40 on 2025-08-22 at $10.10 per share, reducing his holdings from 338,351 to 121,000 shares—a 64.2% reduction in his equity stake. His prior 4 open-market sales at WVE (on 2025-03-07, 2024-11-25, 2024-11-15, and 2024-10-16) all posted negative 90-day returns ranging from -24.6% to -29.5%, indicating a consistent pattern of well-timed exits before subsequent declines. Wave Life Sciences is currently unprofitable (net income $-50.5M in the latest period), operates at a $1.6B market cap, and has contracted revenue year-over-year (-4.4%), factors that warrant scrutiny of the insider's confidence level given the magnitude of this exit relative to his remaining position.

WVE CEO BOLNO sold 169,025 shares at $9.57; stock down 42.8% from 52-week high, down 38.4% in 90 days post-last-sale.

BOLNO PAUL, President and CEO, sold 169,025 shares of Wave Life Sciences Ltd. at $9.57 on 2025-03-07, reducing holdings by 33.3% to 338,351 shares. This sale occurs as the stock trades at $9.40 current price, -42.8% from its 52-week high of $16.44 and down 38.4% over the past 90 days. His three prior sales at WVE (2024-10-16, 2024-11-15, 2024-11-25) all generated negative 90-day returns (-25.8%, -24.6%, -25.8% respectively), with a 100% timing success rate, establishing a pattern of selling ahead of material declines. Fundamentally, WVE is unprofitable with $-61.8M net income on $19.7M quarterly revenue and negative 4.4% annual revenue growth, indicating operational stress. The combination of a 33.3% share reduction by the CEO during a steep downtrend, paired with a historical track record of well-timed exits before further weakness at this same ticker, alongside deteriorating fundamentals, warrants investor scrutiny of the company's near-term outlook.

WVE: CEO Paul Bolno sells 50,000 shares ($750.0K) on 2024-11-25, retaining 217.4K shares as stock trades -8.8% from 52-week high.

CEO Paul Bolno sold 50,000 shares at $15.00 on 2024-11-25, reducing his stake by 18.7% while retaining 217.4K shares. The transaction occurred after a sustained rally—the stock is up 162.5% over the past 90 days—near its 52-week high of $16.44. However, the company remains unprofitable with a net income of $-61.8M against quarterly revenue of $19.7M, despite exceptional annual revenue growth of 3005.1%. Bolno's prior two sales at WVE show a mixed record (one with -8.9% 30-day return), and his cross-ticker track record shows an average 30-day return of -8.9% on prior sells; the current stock is already -8.8% from its 52-week peak, providing limited insight into whether this particular sale will prove well-timed.